<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Indoleamine 2,3-dioxygenases-1 (Ido1) and -2 initiate the <z:chebi fb="0" ids="28683">kynurenine</z:chebi> pathway of tryptophan metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to the established immune regulatory effects of Ido1 and the ability of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> to regulate Ido1 activity, it is now also known that Ido1-mediated metabolism of tryptophan to <z:chebi fb="0" ids="28683">kynurenine</z:chebi> can modulate vascular tone </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="2" ids="37709">Ido</z:chebi> activity is reportedly elevated in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients and correlates with increased risk of <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, the present goals were to test whether, following <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>, <z:chebi fb="2" ids="37709">Ido</z:chebi> activity and cerebrovascular Ido1 expression are altered and whether expression of Ido1 contributes to <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0917805,C0007787" disease_type="Disease or Syndrome" abbrv="">Transient cerebral ischaemia</z:e> was induced in <z:mp ids='MP_0002169'>wild-type</z:mp> and Ido1 gene-deficient (Ido1 (-/-)) mice </plain></SENT>
<SENT sid="5" pm="."><plain>Mice were pre-treated with vehicle, the Ido1 inhibitor, 1-<z:chebi fb="36" ids="29309">methyl</z:chebi>-<z:chebi fb="0" ids="16296,29955">D-tryptophan</z:chebi> (1-MT; 50 mg/kg i.p.) or the inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (Nos2) inhibitor, <z:chebi fb="0" ids="40618">aminoguanidine</z:chebi> (AG, 100 mg/kg i.p.) </plain></SENT>
<SENT sid="6" pm="."><plain>At 24 h, neurological function, brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size and swelling were assessed </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, <z:chebi fb="2" ids="37709">Ido</z:chebi> activity was estimated by plasma <z:chebi fb="0" ids="28683">kynurenine</z:chebi> and tryptophan, and Ido1 expression was examined in cerebral arterioles </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">Cerebral ischaemia</z:e>-reperfusion in <z:mp ids='MP_0002169'>wild-type</z:mp> mice increased <z:chebi fb="2" ids="37709">Ido</z:chebi> activity and its expression in cerebral arterioles </plain></SENT>
<SENT sid="9" pm="."><plain>Ido1 (-/-) and 1-MT-treated <z:mp ids='MP_0002169'>wild-type</z:mp> mice had lower <z:chebi fb="2" ids="37709">Ido</z:chebi> activity but similar post-<z:hpo ids='HP_0001297'>stroke</z:hpo> neurological function and similar total brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and swelling, relative to control mice </plain></SENT>
<SENT sid="10" pm="."><plain>Inhibition of Nos2 with AG also did not affect <z:chebi fb="2" ids="37709">Ido</z:chebi> activity or outcome following <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>This study provides molecular and pharmacological evidence that the expression and the activity of Ido1 increase following <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>However, such Ido1 expression does not appear to affect overall outcome following <z:hpo ids='HP_0011009'>acute</z:hpo> ischaemic <z:hpo ids='HP_0001297'>stroke</z:hpo>, and furthermore, a regulatory role of Nos2-derived nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> on <z:chebi fb="2" ids="37709">Ido</z:chebi> activity following <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>-reperfusion appears unlikely </plain></SENT>
</text></document>